Page last updated: 2024-12-05

emylcamate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

emylcamate: minor descriptor (66-84); on-line & Index Medicus search CARBAMATES (66-84) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	6526
CHEMBL ID	2104208
CHEBI ID	134769
SCHEMBL ID	387718
MeSH ID	M0262661

Synonyms (64)

Synonym
striatran
psicoplegil
wln: zvox2&2&1
emylcamat
3-pentanol, carbamate
nsc169882
nsc169917
nuncital
statran
stratran
3-methyl-3-pentanol carbamate
kab 1925
mk-250
kabi-295
emilcamato
jd-91
restetal
methyl diethyl carbinol urethan
78-28-4
diethyl methyl carbinol urethan
1-ethyl-1-methylpropyl carbamate
91 jd
nsc-169882
striatan
tert-hexanol carbamate
nsc-169917
carbamic acid, 1-ethyl-1-methylpropyl ester
emylcamate
kabi-925
3-pentanol, 3-methyl-, carbamate
nsc 169882
carbamic acid, tert-hexyl ester
terc.hexylester kyseliny karbaminove [czech]
brn 1755436
emylcamatum [inn-latin]
einecs 201-101-4
tert-hexyl carbamate
emylcamate [inn:ban]
emilcamato [inn-spanish]
emylcamate (inn)
D07317
CHEBI:134769
3-methylpentan-3-yl carbamate
AKOS006273433
CHEMBL2104208
kabi 925
kcj747d3r4 ,
emylcamatum
unii-kcj747d3r4
terc.hexylester kyseliny karbaminove
emylcamate [who-dd]
emylcamate [inn]
emylcamate [mi]
DTXSID40228645
SCHEMBL387718
SLWGJZPKHAXZQL-UHFFFAOYSA-N
stratan
ethyl2-phenylpropanoate
Z1198155508
DB13572
Q378997
CS-0081492
HY-121340
EN300-212804

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
carbamate ester	Any ester of carbamic acid or its N-substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (9)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	9 (100.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	40.28 (24.57)
Research Supply Index	2.40 (2.92)
Research Growth Index	4.45 (4.65)
Search Engine Demand Index	56.46 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (40.28)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
carbamates [no description available]	3.54	9	amino-acid anion
meprobamate Meprobamate: A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of ANXIETY DISORDERS, and also for the short-term management of INSOMNIA but has largely been superseded by the BENZODIAZEPINES. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603)	7.34	2	organic molecular entity
urethane [no description available]	1.93	1	carbamate ester	fungal metabolite; mutagen

Condition	Indicated	Relationship Strength	Studies
Behavior Disorders [description not available]	0	2.34	2
Mental Disorders Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.	0	2.34	2
Cerebral Palsy, Athetoid [description not available]	0	1.93	1
Deficiency, Mental [description not available]	0	1.93	1
Clasp-Knife Spasticity [description not available]	0	1.93	1
Cerebral Palsy A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7)	0	1.93	1
Intellectual Disability Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28)	0	1.93	1
Muscle Spasticity A form of muscle hypertonia associated with upper MOTOR NEURON DISEASE. Resistance to passive stretch of a spastic muscle results in minimal initial resistance (a free interval) followed by an incremental increase in muscle tone. Tone increases in proportion to the velocity of stretch. Spasticity is usually accompanied by HYPERREFLEXIA and variable degrees of MUSCLE WEAKNESS. (From Adams et al., Principles of Neurology, 6th ed, p54)	0	1.93	1
Alcohol Abuse [description not available]	0	2.34	2
Anxiety Neuroses [description not available]	0	1.93	1
Chronic Insomnia [description not available]	0	1.93	1
Neuroses [description not available]	0	2.34	2
Alcoholism A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)	0	2.34	2
Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.	1	3.93	1
Anxiety Disorders Persistent and disabling ANXIETY.	0	1.93	1
Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.	0	1.93	1
Sleep Initiation and Maintenance Disorders Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition.	0	1.93	1
Neurotic Disorders Disorders in which the symptoms are distressing to the individual and recognized by him or her as being unacceptable. Social relationships may be greatly affected but usually remain within acceptable limits. The disturbance is relatively enduring or recurrent without treatment.	0	2.34	2
Psychoses [description not available]	0	1.93	1
Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)	0	1.93	1

chemdatabank.com